AN2 Therapeutics, Inc. (ANTX) Investor Relations Documents

AN2 Therapeutics, Inc. (ANTX) investor relations documents from the company's IR site: 1 presentation, 39 press releases; latest deck 2026-08-11. Read in-app with summaries. First-party data.

Investor Presentation: AN2 Therapeutics is advancing epetraborole for Polycythemia Vera and M. abscessus, and AN2-502998 for Chagas disease, with multiple clinical data readouts expected in 2027.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-11PresentationInvestor Presentation
2026-08-11Press releasePress release
2026-08-11Press releaseAN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
2026-06-04Press releasePress release
2026-06-04Press releaseAN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic C
2026-05-21Press releasePress release
2026-05-21Press releaseAN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
2026-05-11Press releasePress release
2026-05-11Press releaseAN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
2026-05-07Press releasePress release
2026-05-07Press releaseAN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
2026-03-31Press releasePress release
2026-03-31Press releaseAN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium
2026-03-17Press releasePress release
2026-03-17Press releaseAN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highligh
2026-03-09Press releasePress release
2026-03-09Press releaseAN2 Therapeutics Announces $40 Million Private Placement Financing
2026-03-03Press releasePress release
2026-03-03Press releaseAN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
2026-02-17Press releasePress release
2026-02-17Press releaseAN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
2026-01-12Press releasePress release
2026-01-12Press releaseAN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole i
2025-11-12Press releasePress release
2025-11-10Press releasePress release
2025-11-10Press releaseAN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosi
2025-11-06Press releasePress release
2025-08-12Press releasePress release
2025-08-12Press releasePress release
2025-08-12Press releaseAN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
2025-07-23Press releasePress release
2025-07-23Press releaseAN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Dis
2025-06-30Press releasePress release
2025-06-30Press releaseAN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for P
2025-05-29Press releasePress release
2025-05-29Press releaseAN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
2025-05-13Press releasePress release
2025-05-01Press releasePress release
2025-05-01Press releaseAN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milest
2025-04-30Press releasePress release

ANTX overview · ANTX earnings · ANTX financials · ANTX KPIs · ANTX ownership · ANTX peers · ANTX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.